ZDHHC21

Across TCGA pan-cancer cohorts, ZDHHC21 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZDHHC21 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZDHHC21 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZDHHC21 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where ZDHHC21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.134	1.000	.038	10	view →
LSCC	OS	Median	II,III,IV	1.000	0.879	.013	5	view →
LUAD	DFS	Tertile	II,III,IV	0.895	0.776	.020	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZDHHC21–HNSC (OS)

Open the HNSC breakdown →